{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T17:57:51Z","timestamp":1783792671364,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s12325-020-01425-8","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T13:12:01Z","timestamp":1594300321000},"page":"3746-3760","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-\u03b1 Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study"],"prefix":"10.1007","volume":"37","author":[{"given":"Johan","family":"Dal\u00e9n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Luttropp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Svedbom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7190-6323","authenticated-orcid":false,"given":"Sumesh","family":"Kachroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"issue":"10055","key":"1425_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023\u201338.","journal-title":"Lancet"},{"issue":"10","key":"1425_CR2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957\u201370.","journal-title":"N Engl J Med"},{"issue":"9","key":"1425_CR3","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1136\/ard.2005.046367","volume":"65","author":"D Huscher","year":"2006","unstructured":"Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis. 2006;65(9):1175\u201383.","journal-title":"Ann Rheum Dis"},{"key":"1425_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1477-7525-7-25","volume":"7","author":"F Salaffi","year":"2009","unstructured":"Salaffi F, Carotti M, Gasparini S, Intorcia M, Grassi W. The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes. 2009;7:25.","journal-title":"Health Qual Life Outcomes"},{"issue":"7","key":"1425_CR5","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.clinthera.2011.06.001","volume":"33","author":"MA Blum","year":"2011","unstructured":"Blum MA, Koo D, Doshi JA. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther. 2011;33(7):901\u201313.","journal-title":"Clin Ther"},{"issue":"10061","key":"1425_CR6","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Burmester GR, Combe B, et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet. 2016;388(10061):2763\u201374.","journal-title":"Lancet"},{"issue":"6","key":"1425_CR7","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1425_CR8","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.clinthera.2015.04.012","volume":"37","author":"O Baser","year":"2015","unstructured":"Baser O, Ganguli A, Roy S, Xie L, Cifaldi M. Impact of switching from an initial tumor necrosis factor inhibitor on health care resource utilization and costs among patients with rheumatoid arthritis. Clin Ther. 2015;37(7):1454\u201365.","journal-title":"Clin Ther"},{"issue":"5","key":"1425_CR9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1080\/13696998.2016.1275653","volume":"20","author":"B Chastek","year":"2017","unstructured":"Chastek B, Becker LK, Chen CI, Mahajan P, Curtis JR. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis. J Med Econ. 2017;20(5):464\u201373.","journal-title":"J Med Econ"},{"issue":"11","key":"1425_CR10","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1007\/s12325-017-0617-5","volume":"34","author":"B Chastek","year":"2017","unstructured":"Chastek B, Chen CI, Proudfoot C, Shinde S, Kuznik A, Wei W. Treatment persistence and healthcare costs among patients with rheumatoid arthritis changing biologics in the USA. Adv Ther. 2017;34(11):2422\u201335.","journal-title":"Adv Ther"},{"key":"1425_CR11","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.","journal-title":"BMC Public Health"},{"issue":"7","key":"1425_CR12","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.1294","volume":"16","author":"B Wettermark","year":"2007","unstructured":"Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug Register\u2014opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726\u201335.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"1425_CR13","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1136\/ard.2005.045872","volume":"65","author":"J Askling","year":"2006","unstructured":"Askling J, Fored CM, Geborek P, et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis. 2006;65(6):707\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1425_CR14","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1136\/annrheumdis-2013-204128","volume":"74","author":"M Neovius","year":"2015","unstructured":"Neovius M, Arkema EV, Olsson H, et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis. 2015;74(2):354\u201360.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1425_CR15","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00296-017-3825-z","volume":"37","author":"J Dalen","year":"2017","unstructured":"Dalen J, Svedbom A, Black CM, Kachroo S. Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors. Rheumatol Int. 2017;37(12):2049\u201358.","journal-title":"Rheumatol Int"},{"issue":"7","key":"1425_CR16","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00296-016-3423-5","volume":"36","author":"J Dalen","year":"2016","unstructured":"Dalen J, Svedbom A, Black CM, et al. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence. Rheumatol Int. 2016;36(7):987\u201395.","journal-title":"Rheumatol Int"},{"key":"1425_CR17","unstructured":"The National Board of Health and Welfare (Socialstyrelsen). Pharmaceuticals\u2014statistics for 2014. 2015. https:\/\/www.socialstyrelsen.se\/globalassets\/sharepoint-dokument\/artikelkatalog\/statistik\/2015-3-17.pdf."},{"key":"1425_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/PPA.S119808","volume":"11","author":"A Svedbom","year":"2017","unstructured":"Svedbom A, Dalen J, Black CM, Kachroo S. Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line. Patient Prefer Adherence. 2017;11:95\u2013106.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"1425_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44\u20137.","journal-title":"Value Health"},{"issue":"19","key":"1425_CR20","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","volume":"17","author":"RB D'Agostino Jr","year":"1998","unstructured":"D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265\u201381.","journal-title":"Stat Med"},{"issue":"1","key":"1425_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41\u201355.","journal-title":"Biometrika"},{"issue":"25","key":"1425_CR22","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083\u2013107.","journal-title":"Stat Med"},{"issue":"3","key":"1425_CR23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/pan\/mpl013","volume":"15","author":"DE Ho","year":"2007","unstructured":"Ho DE. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Political Anal. 2007;15(3):199\u2013236.","journal-title":"Political Anal"},{"issue":"Part 2","key":"1425_CR24","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1467-985X.2007.00527.x","volume":"171","author":"K Imai","year":"2008","unstructured":"Imai K, King G, Stuart EA. Misunderstandings between experimentalists and observationalists about causal inference. J R Stat Soc. 2008;171(Part 2):481\u2013502.","journal-title":"J R Stat Soc"},{"issue":"1","key":"1425_CR25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/00031305.1985.10479383","volume":"39","author":"PR Rosenbaum","year":"1985","unstructured":"Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39(1):33\u20138.","journal-title":"Am Stat"},{"issue":"5","key":"1425_CR26","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2340\/00015555-2329","volume":"96","author":"A Svedbom","year":"2016","unstructured":"Svedbom A, Dahlen J, Mamolo C, et al. Economic burden of psoriasis and potential cost offsets with biologic treatment: a Swedish register analysis. Acta Derm Venereol. 2016;96(5):651\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"1425_CR27","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s12325-016-0371-0","volume":"33","author":"GW Cannon","year":"2016","unstructured":"Cannon GW, DuVall SL, Haroldsen CL, et al. Clinical outcomes and biologic costs of switching between tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis. Adv Ther. 2016;33(8):1347\u201359.","journal-title":"Adv Ther"},{"key":"1425_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/CEOR.S108730","volume":"9","author":"L Degli Esposti","year":"2017","unstructured":"Degli Esposti L, Favalli EG, Sangiorgi D, et al. Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy. Clinicoecon Outcomes Res. 2017;9:9\u201317.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"4","key":"1425_CR29","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3111\/13696998.2014.893241","volume":"17","author":"B Meissner","year":"2014","unstructured":"Meissner B, Trivedi D, You M, Rosenblatt L. Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting. J Med Econ. 2014;17(4):259\u201365.","journal-title":"J Med Econ"},{"issue":"6","key":"1425_CR30","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3111\/13696998.2016.1142448","volume":"19","author":"N Rashid","year":"2016","unstructured":"Rashid N, Lin AT, Aranda G Jr, et al. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system. J Med Econ. 2016;19(6):568\u201375.","journal-title":"J Med Econ"},{"issue":"4","key":"1425_CR31","doi-asserted-by":"publisher","first-page":"A35","DOI":"10.1016\/j.jval.2012.03.198","volume":"15","author":"H Wang","year":"2012","unstructured":"Wang H, Wang Y, Michael T, Hopkins B, Bodoria M, Sondhi M, Covington M. Biologic therapy patterns and associated costs in rheumatoid arthritis patients who initiated a tumor necrosis factor antagonist over two years. Value Health. 2012;15(4):A35.","journal-title":"Value Health"},{"issue":"4","key":"1425_CR32","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1136\/ard.2010.133371","volume":"70","author":"M Neovius","year":"2011","unstructured":"Neovius M, Simard JF, Askling J, group As. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. Ann Rheum Dis. 2011;70(4):624\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1425_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/02841860802247664","volume":"48","author":"L Barlow","year":"2009","unstructured":"Barlow L, Westergren K, Holmberg L, Talback M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009;48(1):27\u201333.","journal-title":"Acta Oncol"},{"key":"1425_CR34","first-page":"527","volume":"77","author":"J Dalen","year":"2018","unstructured":"Dalen J, Svedbom A, Luttropp K, Kachroo S. Costs associated with switching subcutaneous tumour necrosis factor-\u0391 inhibitor in the treatment of immune-mediated rheumatic disease. EULAR. 2018;77:527.","journal-title":"EULAR"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01425-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-020-01425-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01425-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T16:45:17Z","timestamp":1723221917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-020-01425-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,9]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["1425"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01425-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,9]]},"assertion":[{"value":"1 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}